Kala Pharmaceuticals, Inc. (NASDAQ:KALA) was founded in 2009, formerly known as Hanes Newco, Inc., changed its current name in December of the same year, headquartered in Waltham, Massachusetts, USA, with 25 full-time employees (6/ 30/2017), is a biopharmaceutical company focusing on the development and commercialization of new therapies using its proprietary nanoparticle-based Mucus Penetrating Particles Technology.
Kala Pharmaceuticals (KALA):
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of new drugs for the treatment of eye diseases using the company’s proprietary nanoparticle-based colloidal permeable particles (MPP) technology.
Kala Pharmaceuticals’ MPP is a selective size nanoparticle with a proprietary coating. These two key features make the drug particles uniformly distributed on the mucosal surface, and by increasing the fluidity of the drug particles through the mucus and preventing the drug particles from being captured by the mucus And elimination, thereby significantly increasing drug delivery to target tissues.
Kala Pharmaceuticals’ products include:
- KPI-121 1.0%, is a stable MPP nano-suspension of ophthalmic corticosteroids-a phase III clinical trial for the treatment of ocular inflammation after surgery has been completed.
- KPI-121 0.25%, is a stable MPP nano-suspension of ophthalmic corticosteroids-a phase III clinical trial for temporary relief of dry eye symptoms has been completed.
- KPI-285, a small molecule receptor tyrosine kinase inhibitor (RTKi), is used for the potential local treatment of wet age-related macular degeneration (AMD).
KALA expects to submit new drug applications (NDAs) for these drug candidates by the end of 2017 and the first half of 2018.
Kala Pharmaceuticals (KALA) investment:
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) listed on Nasdaq on 7/20/2017 IPO with an issue price of US$15, 6 million shares issued, and a fund-raising of US$90 million, stock code: KALA.